BioNTech Has More Cancer Drugs in Late-Stage Trials Than Most Investors Realize. Is It a Buy Under $100?
Key PointsBioNTech now has more than 25 phase 2 and phase 3 oncology trials underway, with 15 phase 3 trials targeted by the end of 2026.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.